ArticleJournal of enzyme inhibition and medicinal chemistry2019
Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
Article in Journal of enzyme inhibition and medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- A Review of Research from 2012 to 2024 on Pyrazole-based Anticancer Agents with SAR Study.Current topics in medicinal chemistry · 2026Review
- In-vitro and in-silico study to assess anti breast cancer potential of N-tosyl-indole based hydrazones.Scientific reports · 2025Article
- Novel furo[2,3-RSC medicinal chemistry · 2025Article
- Article
- Design, synthesis,RSC advances · 2025Article
- Advances in Small-molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-cancer Agents.Current medicinal chemistry · 2025Review
- Crystal structure determination and analyses of Hirshfeld surface, crystal voids, inter-molecular inter-action energies and energy frameworks of 1-benzyl-4-(methyl-sulfan-yl)-3a,7a-di-hydro-1Acta crystallographica. Section E, Crystallographic communications · 2024Article
- Pyrazolo - Pyrimidines as Targeted Anticancer Scaffolds - A Comprehensive Review.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2024Review
- Thiazolation of phenylthiosemicarbazone to access new thiazoles: anticancer activity and molecular docking.Future medicinal chemistry · 2024Article
- Preliminary anticancer evaluation of new Pd(II) complexes bearing NNO donor ligands.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Novel pyrazolo[3,4-RSC medicinal chemistry · 2023Article
- GC-MS Profiling and Biomedical Applications of Essential Oil ofAntioxidants (Basel, Switzerland) · 2023Article
- Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity.Journal of enzyme inhibition and medicinal chemistry · 2022Article
- Article
- The long non-coding RNA UPAT promotes gastric cancer cell progression via UHRF1.Genes & genomics · 2022Article
- First Report on Comparative Essential Oil Profile of Stem and Leaves ofMetabolites · 2022Article
- Polyoxometalate-based nanocomposites for antitumor and antibacterial applications.Nanoscale advances · 2022Review
- Crystal structure determination, Hirshfeld surface, crystal void, inter-molecular inter-action energy analyses, as well as DFT and energy framework calculations of 2-(4-oxo-4,5-di-hydro-1Acta crystallographica. Section E, Crystallographic communications · 2022Article
- Emerging strategies to overcome resistance to third-generation EGFR inhibitors.Journal of hematology & oncology · 2022Review
- A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure-Activity Relationship.Frontiers in chemistry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A series of novel pyrazolo[3,4-d]pyrimidines was synthesised. Twelve synthesised compounds were evaluated for their anticancer activity against 60 human tumour cell lines by NCI (USA). Compound 7d proved prominent anticancer activity. It showed 1.6-fold more potent anti-proliferative activity against OVCAR-4 cell line with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.